- 著者
-
Jiro Sakamoto
Yugo Yamashita
Takeshi Morimoto
Hidewo Amano
Toru Takase
Seiichi Hiramori
Kitae Kim
Maki Oi
Masaharu Akao
Yohei Kobayashi
Mamoru Toyofuku
Toshiaki Izumi
Tomohisa Tada
Po-Min Chen
Koichiro Murata
Yoshiaki Tsuyuki
Syunsuke Saga
Yuji Nishimoto
Tomoki Sasa
Minako Kinoshita
Kiyonori Togi
Hiroshi Mabuchi
Kensuke Takabayashi
Yusuke Yoshikawa
Hiroki Shiomi
Takao Kato
Takeru Makiyama
Koh Ono
Toshihiro Tamura
Yoshihisa Nakagawa
Takeshi Kimura
on behalf of the COMMAND VTE Registry Investigators
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-19-0515, (Released:2019-09-20)
- 参考文献数
- 28
- 被引用文献数
-
5
57
Background:There is a paucity of data on the management and prognosis of cancer-associated venous thromboembolism (VTE), leading to uncertainty about optimal management strategies.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive acute symptomatic VTE patients in Japan between 2010 and 2014. We divided the entire cohort into 3 groups: active cancer (n=695, 23%), history of cancer (n=243, 8%), and no history of cancer (n=2089, 69%). The rate of anticoagulation discontinuation was higher in patients with active cancer (43.5%, 27.0%, and 27.0%, respectively, at 1 year, P<0.001). The cumulative 5-year incidences of recurrent VTE, major bleeding, and all-cause death were higher in patients with active cancer (recurrent VTE: 17.7%, 10.2%, and 8.6%, P<0.001; major bleeding: 26.6%, 8.8%, and 9.3%, P<0.001; all-cause death: 73.1%, 28.6%, 14.6%, P<0.001). Among the 4 groups classified according to active cancer status, the cumulative 1-year incidence of recurrent VTE was higher in the metastasis group (terminal stage group: 6.4%, metastasis group: 22.1%, under chemotherapy group: 10.8%, and other group: 5.8%, P<0.001).Conclusions:In a current real-world VTE registry, patients with active cancer had higher risk for VTE recurrence, bleeding, and death, with variations according to cancer status, than patients without active cancer. Anticoagulation therapy was frequently discontinued prematurely in patients with active cancer in discordance with current guideline recommendations.